INTEC, IMPAX TO COLLABORATE ON DRUG DEVELOPMENT

Israel-based Intec Pharma has entered into a collaboration agreement with Impax Laboratories to develop a drug using Intec's Accordion Pill technology. Impax specializes in the development and marketing of controlled-release and specialty generics in addition to the development of branded products.

"Impax has a similar approach to that of Teva; they are a generic company but are also interested in developing specialty products," said Intec Pharma CEO Efi Cohen-Arazi.

Intec Pharma recently announced a change in its business strategy under which it would move to independent development of products up to the advanced clinical trials stage.